Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96LT9
UPID:
RNPC3_HUMAN
Alternative names:
RNA-binding motif protein 40; U11/U12 small nuclear ribonucleoprotein 65 kDa protein
Alternative UPACC:
Q96LT9; A8K1C9; D3DT74; Q5TZ87; Q96FK7; Q96JI8; Q9NSU7; Q9NXX2
Background:
RNA-binding region-containing protein 3, also known as RNA-binding motif protein 40 and U11/U12 small nuclear ribonucleoprotein 65 kDa protein, plays a crucial role in pre-mRNA U12-dependent splicing. This process, carried out by the minor spliceosome, is essential for removing U12-type introns, which, although comprising less than 1% of all non-coding sequences, are vital for the correct expression of certain genes. The protein's ability to bind to the 3'-stem-loop of m(7)G-capped U12 snRNA underscores its significance in RNA processing.
Therapeutic significance:
RNA-binding region-containing protein 3 is implicated in Pituitary hormone deficiency, combined or isolated, 7, a condition characterized by severe postnatal growth failure and hypoplasia of the anterior pituitary. This association highlights the protein's potential as a target for therapeutic intervention in growth hormone deficiencies.